HOME >> MEDICINE >> NEWS
PET/CT scanning now available at Fox Chase Cancer Center

PHILADELPHIA Fox Chase Cancer Center is the only institution in the Greater Delaware Valley now offering patients the newest in imaging technology called PET/CT scanning. PET/CT is the fusion of two advanced technologies that combine detailed images of a patient's internal anatomy together with a unique view of cell metabolic function, aiding physicians in detecting and accurately diagnosing various cancers. "PET/CT is the most sophisticated imaging equipment available and we're very excited to now offer this new technology to our patients," says Lee P. Adler, MD, chief of nuclear medicine and senior member at Fox Chase Cancer Center. "This technology will allow us to optimize the treatments we offer patients and ultimately achieve greater success in their care."

PET stands for positron emission tomography and it detects changes in cellular function how cells are utilizing nutrients like sugar and oxygen. Areas with a high degree of metabolic activity have a greater chance of being cancerous. A computerized tomography or CT scan allows physicians to see the internal or anatomical structures within the human body. Together these two technologies make up the revolutionary PET/CT scan that enable Fox Chase physicians to view metabolic activity and pinpoint the location of abnormal lesions to target the disease more precisely.

"When used alone the PET and CT scans are good diagnostic tools, but when combined, they're much superior," says Adler. "The advantage here is the cancer is highlighted on the computer screen. We're able to pinpoint the location of the cancer, determine the extent of the disease, and evaluate the effectiveness of the patient's treatment," says Adler.

The PET/CT unit will be used at Fox Chase to determine if tumors are benign or malignant, to examine if prior therapy has been effective, and to detect if cancer has spread to other parts of the body. This technology will be particularly useful to more accurately diagnos
'"/>

Contact: Sue Montgomery Madden
S_Madden@fccc.edu
215-728-7784
Fox Chase Cancer Center
3-Sep-2002


Page: 1 2

Related medicine news :

1. Combination PET/CT should be used to determine stage of non-small cell lung cancer
2. Whole-body PET/CT scan appears useful for determining tumor stage
3. University of Pittsburgh research shows combined PET/CT finds cancerous lesions standard CT misses
4. PET/CT may identify vulnerable aortic plaque
5. Pet scanning better for heart disease diagnosis, management
6. Brain-scanning technologies need standards, according to Stanford researcher
7. PET scanning promising in diagnosing cancer-related neurological disorders
8. Stanford researchers weigh risks vs. benefits of self-referred body scanning
9. Definition of persistent vegetative state available from American Academy of Neurology
10. Countywide forecasts of water use available for Illinois, Midwest
11. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: PET scanning now available Fox Chase Cancer Center

(Date:5/21/2013)... (PRWEB) May 21, 2013 The nation’s ... lawsuit is nearing its conclusion in Washington state ... during closing statements yesterday, an attorney for the Plaintiffs ... company wanted to tie sales and services for its ... training to keep control of surgeons, to keep control ...
(Date:5/21/2013)... May 21, 2013 Go Classy Tours, ... that they have redesigned their website featuring N ... pool, hot tubs, bars and dining. The website, which ... including sales and guest reviews, will now have a ... itself, including pages on culinary local recipes, flora and ...
(Date:5/21/2013)... 21, 2013 While North Carolina is ... comprehensive travel guides. Brunswick Plantation & Golf Resort is ... include access to 27 holes of "Top10" championship golf. ... North Carolina, knowing the Top 10 from ... away the overwhelming task of selecting the course to ...
(Date:5/21/2013)... About one in six Australian couples suffer infertility, ... one of the fastest growing industries in the health ... conceive naturally through a variety of treatment options, the ... (IVF) cycles. Over the past five years, the number ... 4.4% per annum to a forecast 40,000 cycles in ...
(Date:5/21/2013)... Reporter , , TUESDAY, May 21 (HealthDay News) -- Swollen ... apnea in children, and while removing them did not ... did help them with sleep, behavior and quality of ... a condition that causes abnormal pauses in breathing during ... with the surgery, and those improvements were likely responsible ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... -- U.S. spending on specialty prescription drugs — those ... multiple sclerosis and rheumatoid arthritis — is projected to ... to a forecast released today by Express Scripts (NASDAQ: ... "As we see what,s on the horizon, ... so they can continue to offer an affordable pharmacy ...
(Date:5/21/2013)... , May 21, 2013  AcelRx Pharmaceuticals, ... specialty pharmaceutical company focused on the development ... treatment of acute and breakthrough pain, today ... placebo-controlled Phase 3 study of its investigational ... (NanoTab System), the primary efficacy endpoint was ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
Cached News: